Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
BörsenkürzelALMR
Name des UnternehmensAlamar Biosciences Inc
IPO-datumApr 17, 2026
CEOLuo (Yuling)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse47071 Bayside Pkwy
StadtFREMONT
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94538
Telefon15106269888
Websitehttps://alamarbio.com
BörsenkürzelALMR
IPO-datumApr 17, 2026
CEOLuo (Yuling)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten